Study Shows Oncotype DX and PAM50 Breast Cancer Tests Disagree on Intermediate Risk Group

Two genomic tests for cancer risk recurrence -- Oncotype DX and PAM50 -- show reasonable agreement on high- and low-risk categories but do not agree in their classification of intermediate-risk patients, according to a recent comparison of the assays.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.